Table 3.
The results and statistical comparisons of the pretreatment (week 0) and posttreatment (after 4, 12, 24 and 48 weeks) evaluation parameters in CFO group.
| N=40 | Baseline | 4th week | 12th week | 24th week | 48th week | P (baseline- 48th week) |
|---|---|---|---|---|---|---|
| VAS rest | 5,4±2,2 (4-8) | 4,1±1,8 (3-6) | 3,1±1,8 (1-5) | 3,4±1,7 (2-6) | 3,7±1,9 (2-6) | <0.001 |
| VAS walking | 7.4±2,1 (5-10) | 5,3±2,0 (3-8) | 4,8±1,9(2-7) | 4,2±1,6 (2-7) | 4,1±1,7 (2-6) | <0.001 |
| VAS morning | 6,6±1,8 (5-10) | 5,2±1,8 (3-8) | 4,4±1,6 (3-7) | 3,9±1,5 (2-7) | 4,1±1,5 (3-7) | <0.001 |
| VAS evening | 7,5±2,1 (6-10) | 5,8±2,1 (4-8) | 5,0±1,8 (3-8) | 4,7±1,8 (3-7) | 4,5±1,7 (3-7) | <0.001 |
| FFI total score (34-136) | 82,5±22,9 | 63,9±21,1 | 59,3±19,7 | 55,2±18,7 | 51,8±18,1 | <0.001 |
| FHSQ, FP (0-100) | 34,4±20,4 | 56.9±20,1 | 61,8±23,4 | 60,2±20,2 | 56,2±22,1 | <0.001 |
| FHSQ, FF (0-100) | 51,3±21,3 | 74,9±17,3 | 78,1±18,1 | 80,2±17,9 | 73,0±16,9 | <0.001 |
| FHSQ, FW (0-100) | 32,7±15,4 | 43,2±20,1 | 46,8±20,8 | 47,5±20,7 | 44,7±19,8 | <0.001 |
| FHSQ, GFH (0-100) | 18,6±17,8 | 31,6±20,5 | 37,7±26,3 | 40,6±28,8 | 39,6±27,8 | <0.001 |
| FHSQ, GH (0-100) | 56,2±24,6 | 66,2±25,3 | 69,8±25,7 | 69,9±26,2 | 64,9±25,2 | 0,004 |
| FHSQ, PA (0-100) | 51,2±21,5 | 68,4±21,4 | 73,7±22,3 | 71,4±23,3 | 70,1±21,8 | <0.001 |
| FHSQ, SC (0-100) | 59,4±23,1 | 75,3±25,1 | 76,7±24,2 | 77,1±22,3 | 75,1±22,1 | <0.001 |
| FHSQ, V (0-100) | 44,4±18,6 | 57,7±21,5 | 58,9±19,3 | 59,1±20,7 | 62,8±21,6 | <0.001 |
VAS, Visual Analog Scale; (lower score indicating better function). FFI-R Revised Foot Function Index; (lower score indicating better function). FHSQ, Foot Health Status Questionnaire (FP Foot pain, FF Foot function, FW Footwear, GFH General foot health, GH General health, PA Physical activity, SC Social capacity and V Vigor) (higher score indicating better function).